Optimal multistage designs for randomised clinical trials with continuous outcomes

Statistics in Medicine

Volumn 31, Issue 4, 2012, Pages 301-312

  Wason, James M S ^a   Mander, Adrian P ^a   Thompson, Simon G ^a  

^a MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

Admissible design; Optimal design; Phase II clinical trial; Simulated annealing

Indexed keywords

ARTICLE; CLINICAL RESEARCH; INFORMATION PROCESSING; MATHEMATICAL ANALYSIS; PROBABILITY; PROCESS OPTIMIZATION; SAMPLE SIZE; SIMULATION; STATISTICS; STUDY DESIGN;

ANALGESICS; COMPUTER SIMULATION; DIABETIC NEPHROPATHIES; HUMANS; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84855953899     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4421     Document Type: Article

References (23)

1. Pocock S. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977;64:191-199.
2. O'Brien P, Flemming T. A multiple-testing procedure for clinical trials. Biometrics 1979;35:549-556.
3. Shuster J. Optimal two-stage designs for single-arm phase II cancer trials. Journal of Biopharmaceutical Statistics 2002;22:39-51.
4. Wason J, Mander A. Minimising the maximum expected sample size in two-stage phase II clinical trials with continuous outcomes. Journal of Biopharmaceutical Statistics In press.
5. Whitehead J, Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics 1983;39:227-236.
6. Lai T. Optimal stopping and sequential tests which minimise the maximum expected sample size. Annals of Statistics 1973;1:659-673.
7. Jung S, Lee T, Kim K, George S. Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine 2004;23:561-569.
8. Storer B. A class of phase II designs with three possible outcomes. Biometrics 1992;48:55-60.
9. Sargent D, Chan V, Goldberg M. A three outcome design for phase II clinical trials. Controlled Clinical Trials 2001;22:117-125.
10. Jennison C, Turnbull B. Group Sequential Methods with Applications to Clinical Trials, Chapman and Hall:Boca Raton, 2000.
11. Genz A, Bretz F. Methods for the computation of multivariate t-probabilities. Journal of Computational and Graphical Statistics 2002;11:950-971.
12. Jennison C. Efficient group sequential tests with unpredictable group sizes. Biometrika 1987;74:155-165.
13. Eales JD, Jennison C. An improved method for deriving optimal one-sided group sequential tests. Biometrika 1992;79:13-24.
14. Eales JD, Jennison C. Optimal two-sided group sequential tests. Sequential Analysis 1995;14:273-286.
15. Barber S, Jennison C. Optimal asymmetric one-sided group sequential tests. Biometrika 2002;89:49-60.
16. Lin D, Geyer C. Computational methods for semiparametric linear regression with censored data. Journal of Computational and Graphical Statistics 1992;1:77-90.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989;10:1-10.
18. Whitehead J, Valdes-Marquez E, Lissmats A. A simple two-stage design for quantitative responses with application to a study in diabetic neuropathic pain. Pharmaceutical statistics 2009;8:125-135.
19. DeGroot M. Optimal Statistical Decisions, McGraw-Hill:New York, 1970.
20. Mander A, Thompson S. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. Contemporary Clinical Trials 2010;31:572-578.
21. Proschan M. Sample size re-estimation in clinical trials. Biometrical Journal 2009;51:348-357.
22. 2 and F tests for general linear models. Sequential Analysis16:295-317.
23. Shao J, Feng H. Group sequential t-tests for clinical trials with small sample sizes across stages. Contemporary Clinical Trials 2007;28:563-571.